Who are Sodium Nitroprusside's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natrecor, Monoket, nitroglycerine, Atriopeptin, Remodulin, Flolan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nitroprusside.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sodium Nitroprusside — Competitive Intelligence Brief

Sodium Nitroprusside (NITROPRUSSIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasodilator. Area: Cardiovascular.

marketed Vasodilator Atrial natriuretic peptide receptor 1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sodium Nitroprusside (NITROPRUSSIDE) — Roche.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sodium Nitroprusside TARGET	NITROPRUSSIDE	Roche	marketed	Vasodilator	Atrial natriuretic peptide receptor 1	1974-01-01
Natrecor	NESIRITIDE	Scios Llc	marketed	Natriuretic Peptide	Atrial natriuretic peptide receptor 1	2001-01-01
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
nitroglycerine	nitroglycerine	University Hospital, Ghent	marketed		Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase
Atriopeptin	CARPERITIDE		phase 3	carperitide	Atrial natriuretic peptide receptor 1, Atrial natriuretic peptide receptor 1
Remodulin	TREPROSTINIL	United Therap	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	2002-01-01
Flolan	EPOPROSTENOL	AstraZeneca	marketed	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasodilator class)

Roche · 1 drug in this class
The Cleveland Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sodium Nitroprusside — Competitive Intelligence Brief. https://druglandscape.com/ci/nitroprusside. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab